Immix Biopharma, Inc.

IMMX • Biotechnology

$8.91

▲ +0.69 (+8.39%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$568.20M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.01Liquidez saludable · 10.01Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 16 ago 2026, 12:07 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$8.91

Change8.39%

Shares Out63.77M

Market Cap$568.20M

Enterprise Value$337.10M

52W Range1.94 - 12.14

Beta0.11

P/E-14.23

P/B2.48

P/FCF-14.54

EV/EBITDA-8.14

EV/FCF-8.62

Price$8.91

Change8.39%

Shares Out63.77M

Market Cap$568.20M

Enterprise Value$337.10M

52W Range1.94 - 12.14

Beta0.11

P/E-14.23

P/B2.48

P/FCF-14.54

EV/EBITDA-8.14

EV/FCF-8.62

Earnings Yield-7.03%

FCF Yield-6.88%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.01

Current Ratio10.01

Quick Ratio10.01

Target$23.67

Target Upside165.66%

Target Median$25.00

Target Range20.00 - 26.00

Volume1.29M

Avg Volume1.51M

EPS Surprise0.00

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

88/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.01Liquidez saludable · 10.01Rentabilidad débil

Analyst view

Analyst sentiment and price target

IMMX

Analyst sentiment

Based on 6 analyst votes · 2026-10-21

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-16

Bajo

$19.00

Promedio

$22.00

Mediana

$22.00

Alto

$25.00

Resumen de la compañía

IPO: 12/16/2021

Industria: Biotechnology

P/B i: 2.48

Deuda / Patrimonio i: 0.01

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 10.01

Ratio rápido: 10.01

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

BUCHAN JANE

Transacción: 05/22/2026

COMPRA

Cambio

+12,500

Precio

$8.78

Presentación

05/29/2026

Tipo

COMPRA

BUCHAN JANE

Transacción: 05/22/2026

COMPRA

Cambio

+6,250

Precio

Not reported

Presentación

05/29/2026

Tipo

COMPRA

Hsu Jason

Transacción: 05/22/2026

COMPRA

Cambio

+12,500

Precio

$8.78

Presentación

05/29/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
BUCHAN JANE	COMPRA	+12,500	$8.78	05/22/2026	05/29/2026
BUCHAN JANE	COMPRA	+6,250	Not reported	05/22/2026	05/29/2026
Hsu Jason	COMPRA	+12,500	$8.78	05/22/2026	05/29/2026
Hsu Jason	COMPRA	+6,250	Not reported	05/22/2026	05/29/2026
Chudnovsky Yekaterina	COMPRA	+6,250	Not reported	05/22/2026	05/29/2026
Chudnovsky Yekaterina	COMPRA	+12,500	$8.78	05/22/2026	05/29/2026
Rachman Ilya M	COMPRA	+500,000	$8.78	05/22/2026	05/29/2026
CHANG NANCY T	COMPRA	+12,500	$8.78	05/22/2026	05/29/2026
CHANG NANCY T	COMPRA	+6,250	Not reported	05/22/2026	05/29/2026
Morris Gabriel S	COMPRA	+500,000	$8.78	05/22/2026	05/29/2026
Marquet Magda	COMPRA	+12,500	$8.78	05/22/2026	05/29/2026
Marquet Magda	COMPRA	+6,250	Not reported	05/22/2026	05/29/2026
Ng Carey	COMPRA	+12,500	$8.78	05/22/2026	05/29/2026
Ng Carey	COMPRA	+6,250	Not reported	05/22/2026	05/29/2026
Adams Helen C.	COMPRA	+12,500	$8.78	05/22/2026	05/29/2026
Adams Helen C.	COMPRA	+6,250	Not reported	05/22/2026	05/29/2026
CHANG NANCY T	COMPRA	+39,643	$4.33	11/21/2025	12/11/2025
Morris Gabriel S	COMPRA	+770	$6.58	12/10/2025	12/10/2025
Rachman Ilya M	COMPRA	+746	$6.67	12/10/2025	12/10/2025
Morris Gabriel S	VENTA	-60,000	$0.80	12/08/2025	12/10/2025

Sobre la compañía

Immix Biopharma, Inc.

Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.

Fuente - Link

Competidores

ATOS COYA MGNX ONCY ORMP PLRX SRZN TIL WHWK ZNTL

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. Morgan Healthcare Conference being held January 11-14, 2027 in San Francisco, CA.

GlobeNewsWire

Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study

Immix Biopharma (NASDAQ: IMMX) reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis, and outlined plans for a biologics license application, a frontline study and a targeted commercial launch strategy. AL amyloidosis is a disease in which plasma cells produce toxic light-chain fragments that can damage organs

Defense World

Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study

Immix Biopharma NASDAQ: IMMX reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis, and outlined plans for a biologics license application, a frontline study and a targeted commercial launch strategy.

MarketBeat

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share.

GlobeNewsWire

Immix Biopharma (NASDAQ:IMMX) Stock Jumps 4.1% – Should You Buy?

Shares of Immix Biopharma, Inc. (NASDAQ: IMMX - Get Free Report) rose 4.1% during trading on Monday. The stock traded as high as $11.37 and last traded at $11.4250. 314,931 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 1,286,555 shares. The stock had previously closed at $10.97. Key

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	-0.18055	-0.18	0.00055
2026-03-25	-0.21	-0.27	-0.06
2025-11-07	-0.19	-0.24	-0.05
2025-08-08	-0.21	-0.22	-0.01
2025-05-08	-0.23	-0.15	0.08
2025-03-24	-0.25	-0.16	0.09
2024-11-12	-0.16	-0.24	-0.08
2024-08-12	-0.21	-0.15	0.06
2024-05-09	-0.23	-0.22	0.01
2024-03-29	-0.23	-0.24	-0.01
2023-11-09	-0.23	-0.23	0
2023-08-11	-0.17	-0.24	-0.07